Affinity DataIC50: 0.300nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 0.600nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 2.10nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.70nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 4.5nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 4.80nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
Affinity DataIC50: 5.30nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 6.40nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
Affinity DataIC50: 6.5nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 8nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibitory activity against 5-lipoxygenase(5-LO) using broken rat barophilic leukemia cells (RBL-1)More data for this Ligand-Target Pair
TargetProstaglandin G/H synthase 1/2(RAT)
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)More data for this Ligand-Target Pair
TargetProstaglandin G/H synthase 1/2(RAT)
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Binding affinity determined by ability to displace [3H]-R5020 radioligand using uterine progesterone receptor obtained from estrogen-primed rabbitMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta [7-25](Oryctolagus cuniculus (rabbit))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 26nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
TargetProstaglandin G/H synthase 1/2(RAT)
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)More data for this Ligand-Target Pair